Clinical Trial: Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.

U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07645534) titled 'Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.' on May 12.

Brief Summary: This study aims to evaluate the safety and pharmacokinetic profile of the active ingredients Ingavirin forte, capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) relative to single-entity Drug Ingavirin, capsules, 90 mg following administration under fasting and fed conditions.

Study Start Date: July 11, 2025

Study Type: INTERVENTIONAL

Condition: Influenza Acute Respiratory Viral Infections

Intervention: DRUG: Ingavirin forte, ...